Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy

Abstract

Promising cancer immunotherapeutics depend on mobilization of cytotoxic T cells across tumor vascular barriers through mechanisms that are poorly understood. Recently, we discovered that the CXCR3 chemokine receptor uniquely functions as the master-regulator of cytotoxic CD8+ T cell extravasation and tumor control despite the multiplicity of chemokines available in the tumor landscape.